Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients fulfilled the 1997 ACR modified or SLICC classification criteria of SLE；~2. New onset thrombocytopenia: platelet count \<30X109/L(by both routine test and citric acid anti-coagulated blood count test) within 3 months~Exclusion Criteria:~1. Thrombocytopenia caused by other reasons, including drugs；~2. Positive for active HAV(hepatitis A virus)/HBV(hepatitis B virus) infection~3. Active HIV(human immunodeficiency virus) or HCV(hepatitis C virus) infection;~4. Active HP(Helicopter pylori) infection;~5. Severe liver and kidney dysfunction；~6. Severe neuropsychiatric lupus；~7. No response to high dose steroid and/or cyclophosphamide 1 month prior to study enrollment；~8. Uncontrolled diabetes or hypertension before entry~9. Active GI bleeding 3 months before entry~10. Intolerant to HCQ in the past treatment history；~11. Severe bone marrow suppression or liver damage caused by cyclophosphamide in the past history；~12. Active infection , including bacteria, virus, fungi, mycobacteria~13. Allergy to any of the study medications~14. Confirmed TTP(thrombolic thrombocytopenic purpura)or CAPS(catastrophic anti-phosphilipid syndrome)~15. Platelet count less than 20X109/L with active bleeding~16. Myelodysplastic diseases~17. Patients with heart and lung function impairment~18. thiopurine S-methyltransferase (TPMT) gene positive -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Group1:Hydroxychloroquine (Type: ACTIVE_COMPARATOR): Hydroxychloroquine: 100 mg tablets by mouth, 400mg everyday for 12 months Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months
- Group 2:Cyclophosphamide (Type: ACTIVE_COMPARATOR): Cyclophosphamide, Azathioprine \& Methylprednisolone Cyclophosphamide: 200mg powder intravenous infusion, 1000mg every month for 6 month.~Azathioprine: 100 mg tablets by mouth, everyday for 6 months. Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).